World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
82
Citations
22937
World Ranking
1512
National Ranking
761

Overview

Martin A. Cheever is affiliated with the University of Washington in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focused emphasis on Oncology, Immunology, Dermatology, Pathology and Forensic Medicine, and Molecular Biology.

The scientist's work concentrates on several main topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cutaneous lymphoproliferative disorders research
  • Lymphoma Diagnosis and Treatment
  • T-cell and B-cell Immunology
  • Viral-associated cancers and disorders

Martin A. Cheever has frequently published in a range of journals, with the most common venues being:

  • Journal for ImmunoTherapy of Cancer
  • Clinical Cancer Research
  • Science Translational Medicine
  • Cancer Research
  • Nature Communications

Notable recent papers authored or co-authored by Martin A. Cheever include:

  • "Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma," 2021, Nature Communications
  • "Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer," 2021, Clinical Cancer Research
  • "Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma," 2021, Journal for ImmunoTherapy of Cancer
  • "Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets," 2020, Nature Cancer
  • "Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy," 2022, Science Translational Medicine

The scientist collaborates regularly with several co-authors, including:

  • Steven P. Fling
  • Nirasha Ramchurren
  • Leonard D'Amico
  • Judith C. Kaiser
  • Chihiro Morishima

Best Publications

  • The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

    Martin A. Cheever;Martin A. Cheever;James P. Allison;Andrea S. Ferris;Olivera J. Finn

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  • PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

    Martin A. Cheever;Celestia S. Higano

  • Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

    Mary L. Disis;Emanuel Calenoff;Graham McLaughlin;Ann E. Murphy

  • Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia

    E D Thomas;R A Clift;A Fefer;F R Appelbaum

  • Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

    Mary L. Disis;Theodore A. Gooley;Kristine Rinn;Donna Davis

  • Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

    Mary L. Disis;Kenneth H. Grabstein;Paul R. Sleath;Martin A. Cheever

  • Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

    Mary L. Disis;Helga Bernhard;Faith M. Shiota;Susan L. Hand

  • High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

    Mary L. Disis;Serenella M. Pupa;Julie R. Gralow;Ruggero Dittadi

  • Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

    P D Greenberg;M A Cheever;A Fefer

  • Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.

    Philip D. Greenberg;Donald E. Kern;Martin A. Cheever

  • Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

    M A Cheever;P D Greenberg;A Fefer;S Gillis

  • Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood

    Helga Bernhard;Mary L. Disis;Shelly Heimfeld;Susan Hand

  • Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity

    Keith L. Knutson;Kathy Schiffman;Martin A. Cheever;Mary L. Disis

  • Twelve immunotherapy drugs that could cure cancers

    Unknown

  • Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

    Mary L. Disis;Julie R. Gralow;Helga Bernhard;Susan L. Hand

  • Identification of Genes Overexpressed in Head and Neck Squamous Cell Carcinoma Using a Combination of Complementary DNA Subtraction and Microarray Analysis

    Douglas B. Villaret;Tongtong Wang;Davin Dillon;Jiangchun Xu

  • HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

    Mary L. Disis;Martin A. Cheever

  • T-cell immunity to the joining region of p210BCR-ABL protein

    Wei Chen;David J. Peace;Douglas K. Rovira;Sheng Guo You

  • Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia: A Prospective Comparison

    Appelbaum Fr;Dahlberg S;Thomas Ed;Buckner Cd

  • Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.

    Alexander Gaiger;Valerie Reese;Valerie Reese;Mary L. Disis;Mary L. Disis;Martin A. Cheever;Martin A. Cheever

  • In Vitro Generation of Human Cytolytic T-Cells Specific for Peptides Derived from the HER-2/neu Protooncogene Protein

    Mary L. Disis;Joseph W. Smith;Ann E. Murphy;Wei Chen

  • Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

    Unknown

Frequent Co-Authors

Alexander Fefer
Alexander Fefer University of Washington
Philip D. Greenberg
Philip D. Greenberg Fred Hutchinson Cancer Research Center
Mary L. Disis
Mary L. Disis University of Washington
E. Donnall Thomas
E. Donnall Thomas University of Washington
Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Julie R. Gralow
Julie R. Gralow American Society of Clinical Oncology
Wei Chen
Wei Chen University of Minnesota
Keith M. Sullivan
Keith M. Sullivan Duke University
Jean E. Sanders
Jean E. Sanders Fred Hutchinson Cancer Research Center
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens diverse career opportunities in healthcare and research. Many students pivot into nursing roles to gain clinical experience, making programs like the best online RN programs for non nurses a popular choice. These programs cater to individuals transitioning into nursing without prior experience, bridging gaps efficiently.

For those seeking quicker entry into nursing, accelerated options like absn programs with high acceptance rates provide accessible pathways. These programs are designed to fast-track learning while maintaining quality education standards.

Additionally, practical nursing is a viable pathway through accredited LPN programs easy to get into. These prepare students for essential caregiving roles, often requiring shorter study durations and offering flexible scheduling.

For advanced practice, exploring easy nurse practitioner programs to get into can help immunology graduates enhance their scope of practice. These programs balance accessibility with the depth of training needed for autonomous patient care.

Best Scientists Citing Martin A. Cheever

Trending Scientists